Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes

Cited by (999)

Items 201–300 of 999

1. Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis
   D Shyangdan, Pamela Royle, Christine Clar, Pawana Sharma, Norman R Waugh · 2010 · BMC Endocrine Disorders
2. Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review
   Amrita Ostawal, Emina Mocevic, Nana Kragh, Weiwei Xu · 2016 · Diabetes Therapy
3. Diabetes and obesity: therapeutic targeting and risk reduction – a complex interplay
   Kevin Dean Niswender · 2009 · Diabetes Obesity and Metabolism
4. Short-Term Intervention with Liraglutide Improved Eating Behavior in Obese Women with Polycystic Ovary Syndrome
   Jensterle, Mojca, Kocjan, Tomaz, Kravos, Nika Aleksandra, Pfeifer, Marija, Janez, Andrej · 2015 · Endocrine Research
5. Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients
   Chun-Jun Li, Qian Yu, Pei Yu, Tie-Lian Yu, Qiumei Zhang, Shan Lu, De-Min Yu · 2014 · Cardiovascular Diabetology
6. The Impact of Weight Gain on Motivation, Compliance, and Metabolic Control in Patients with Type 2 Diabetes Mellitus
   Xavier Pi-Sunyer · 2009 · Postgraduate Medicine
7. Mild Renal Impairment and the Efficacy and Safety of Liraglutide
   Jaime A. Davidson, Jason Brett, Ali Falahati, David Scott · 2010 · Endocrine Practice
8. Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials
   Besmir Nreu, Ilaria Dicembrini, Federico Tinti, Giorgio Sesti, Edoardo Mannucci, Matteo Monami · 2020 · Nutrition Metabolism and Cardiovascular Diseases
9. Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors
   Manfredi Rizzo, Ali Abbas Rizvi, Giatgen A. Spinas, Giovam Battista Rini, Kaspar K. Berneis · 2009 · Expert Opinion on Investigational Drugs
10. Cardiovascular Effects of Glucagonlike peptide–1 Agonists
    Michael H. Davidson · 2011 · The American Journal of Cardiology
11. Treatment of prediabetes
    Mustafa Kanat, Ralph A. DeFronzo, Muhammad A Abdul‐Ghani · 2015 · World Journal of Diabetes
12. Weight Beneficial Treatments for Type 2 Diabetes
    L. F. Meneghini, Domingo Orozco‐Beltrán, Kamlesh Khunti, Salvatore Caputo, T. Damçi, Andreas Liebl, S. A. Ross · 2011 · The Journal of Clinical Endocrinology & Metabolism
13. Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials
    Sushrima Gan, Adem Y. Dawed, Louise A. Donnelly, Anand Thakarakkattil Narayanan Nair, Colin N.A. Palmer, Viswanathan Mohan, Ewan R. Pearson · 2020 · Diabetes Care
14. Pharmacotherapy for childhood obesity: present and future prospects
    Roya Sherafat‐Kazemzadeh, Susan Zelitch Yanovski, Jack Adam Yanovski · 2012 · International Journal of Obesity
15. Semaglutide-mediated protection against Aβ correlated with enhancement of autophagy and inhibition of apotosis
    Yan-fang Chang, Di Zhang, Weimin Hu, Dong-Xing Liu, Lin Li · 2020 · Journal of Clinical Neuroscience
16. An overview of the pharmacokinetics, efficacy and safety of liraglutide
    Bruce W. Bode · 2012 · Diabetes Research and Clinical Practice
17. GLP ‐1 Receptor Agonists: Effects on Cardiovascular Risk Reduction
    Daniel Lorber · 2013 · Cardiovascular Therapeutics
18. Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus
    David R. Owens, L. Monnier, Geremia B. Bolli · 2013 · Diabetes & Metabolism
19. Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin
    Anna Vanderheiden, Lindsay Harrison, Jeremy T. Warshauer, BEVERLEY A. ADAMS-HUET, Xilong Li, Qing Yuan, Keith Hulsey, Ivan E. Dimitrov, Takeshi Yokoo, Adam W. Jaster et al. · 2016 · The Journal of Clinical Endocrinology & Metabolism
20. Bone resorption is unchanged by liraglutide in type 2 diabetes patients: A randomised controlled trial
    Katrine Hygum, Torben Harsløf, Niklas Rye Jørgensen, Jørgen Rungby, Steen B. Pedersen, Bente Lomholt Langdahl · 2019 · Bone
21. Patient‐reported outcomes following treatment with the human GLP‐1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes
    Bruce W. Bode, Marcia A. Testa, MELISSA L. MAGWIRE, Paula M. Hale, Mette Hammer, Lawrence Blonde, Alan J. Garber, on behalf of the LEAD‐3 Study Group · 2010 · Diabetes Obesity and Metabolism
22. Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure
    Franco Arturi, Elena Succurro, Sofia Miceli, Cosima Cloro, Mariafrancesca Ruffo, Raffaele Maio, Maria Perticone, Giorgio Sesti, Francesco Perticone · 2016 · Endocrine
23. MEDI0382, a GLP‐1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single‐dose, healthy‐subject, randomized, Phase 1 study
    Ambery, Philip D., Klammt, Sebastian, Posch, Maximillian G., Petrone, Marcella, Pu, Wenji, Rondinone, Cristina, Jermutus, Lutz, Hirshberg, Boaz · 2018 · British Journal of Clinical Pharmacology
24. Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial
    Anholm, Christian, Kumarathurai, Preman, Pedersen, Lene Rørholm, Samkani, Amirsalar, Walzem, Rosemary L., Nielsen, Olav Wendelboe, Kristiansen, Ole Peter, Fenger, Mogens, Madsbad, Sten, Sajadieh, Ahmad et al. · 2019 · Atherosclerosis
25. Chitosan-based therapeutic nanoparticles for combination gene therapy and gene silencing of in vitro cell lines relevant to type 2 diabetes
    Myriam Jean, Mohamad‐Gabriel Alameh, Diogo De Jesus, Marc Thibault, Marc Lavertu, Vincent Darras, Monica Iliescu Nelea, Michael D. Buschmann, Abderrazzak Merzouki · 2011 · European Journal of Pharmaceutical Sciences
26. Potential of liraglutide in the treatment of patients with type 2 diabetes
    Carolyn Fiona Deacon · 2009 · Vascular Health and Risk Management
27. Recent advances in incretin‐based therapies
    David L Russell-Jones, Stephen C. L. Gough · 2012 · Clinical Endocrinology
28. Efficacy and safety of incretin-based therapies: Clinical trial data
    John Raymond White · 2009 · Journal of the American Pharmacists Association
29. Emerging treatment options for type 2 diabetes
    Milan K. Piya, Abd A. Tahrani, Anthony H Barnett · 2010 · British Journal of Clinical Pharmacology
30. Chronic Administration of the Glucagon-Like Peptide-1 Analog, Liraglutide, Delays the Onset of Diabetes and Lowers Triglycerides in UCD-T2DM Rats
    Bethany P. Cummings, Kimber L. Stanhope, James Lawrence Graham, Denis G. Baskin, Steven C. Griffen, Cecilia Nilsson, Anette Graven Sams, Lotte Bjerre Knudsen, Kirsten Raun, Peter Joseph Havel · 2010 · Diabetes
31. Retrospective Study of Adherence to Glucagon-like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes Mellitus in the United States
    Stephen S. Johnston, Hiep P. Nguyen, Eugene Felber, Katherine A. Cappell, James K. Nelson, Bong Chul Chu, Iftekhar D. Kalsekar · 2014 · Advances in Therapy
32. Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future
    Omolara Adetunji, Sanjay Kalra, ManashP Baruah, Rakesh Kumar Sahay, AmbikaGopalakrishnan Unnikrishnan, Shweta Uppal · 2016 · Indian Journal of Endocrinology and Metabolism
33. Novel GLP-1 receptor agonists for diabetes
    Garber, Alan J · 2012 · Expert Opinion on Investigational Drugs
34. Effects of liraglutide compared with placebo on events of acute gallbladder or biliary disease in patients with type 2 diabetes at high risk for cardiovascular events in the LEADER randomized trial.
    Nauck, Michael A., Muus Ghorbani, Marie Louise, Kreiner, Eskil, Saevereid, Hans A., Buse, John B., the LEADER Publication Committee on behalf of the LEADER Trial Investigators · 2019 · Diabetes Care
35. Cardiovascular Comorbidities of Type 2 Diabetes Mellitus: Defining the Potential of Glucagonlike peptide–1-Based Therapies
    ROBERT J. CHILTON, Jamison Wyatt, Shailesh Nandish, RENE A. OLIVEROS, Michael Lujan · 2010 · The American Journal of Medicine
36. Type 2 diabetes mellitus—current therapies and the emergence of surgical options
    Harold E. Lebovitz · 2011 · Nature Reviews Endocrinology
37. Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes
    Savchenko Lg, Наталія Іванівна Дігтяр, Людмила Григорівна Селіхова, Е І Кайдашева, O. A. Shlykova, L. E. Vesnina, Ігор Петрович Кайдашев · 2019 · Romanian Journal of Internal Medicine
38. Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT)
    Helena M. de Wit, Gerald Vervoort, Henry J Jansen, Wim J. C. de Grauw, Bastiaan E. de Galan, Cees J. Tack · 2014 · Diabetologia
39. Liraglutide Effect and Action in Diabetes (LEAD™) trial
    Sten Madsbad · 2009 · Expert Review of Endocrinology & Metabolism
40. Cardiovascular safety of anti-diabetic drugs
    Rekha B. Kumar, David M. Kerins, Thomas Walther · 2015 · European Heart Journal - Cardiovascular Pharmacotherapy
41. Effects of Incretin Hormones on β-Cell Mass and Function, Body Weight, and Hepatic and Myocardial Function
    Sunder Raj D. Mudaliar, Robert R. Henry · 2010 · The American Journal of Medicine
42. Health Economic Evaluation of Type 2 Diabetes Mellitus: A Clinical Practice Focused Review
    Andreas Liebl, Kamlesh K. Khunti, Domingo Orozco‐Beltrán, Jean‐François Yale · 2015 · Clinical Medicine Insights Endocrinology and Diabetes
43. Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial
    Stewart B. Harris, Győző Kocsis, Rudolf Prager, Terry Ridge, Keval Chandarana, Natalie Halladin, Serge A Jabbour · 2017 · Diabetes Obesity and Metabolism
44. Liraglutide – overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes
    Melanie Jane Davies, Ram Kela, Kamlesh Khunti · 2010 · Diabetes Obesity and Metabolism
45. Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes
    Julie A. Lovshin · 2017 · Canadian Journal of Diabetes
46. Initial Combination Therapy for Type 2 Diabetes Mellitus: Is It Ready for Prime Time?
    Bernard Zinman · 2010 · The American Journal of Medicine
47. A randomized controlled trial comparing the GLP ‐1 receptor agonist liraglutide to a sulphonylurea as add on to metformin in patients with established type 2 diabetes during Ramadan: the Treat 4 Ramadan Trial
    Emer M. Brady, Melanie Jane Davies, Laura J. Gray, Mujahid Ahmad Saeed, D. Smith, Wasim Hanif, Kamlesh K. Khunti · 2013 · Diabetes Obesity and Metabolism
48. Comparisons of weight changes between sodium‐glucose cotransporter 2 inhibitors treatment and glucagon‐like peptide‐1 analogs treatment in type 2 diabetes patients: A meta‐analysis
    Xiaoling Cai, Liwei Ji, Yifei Chen, Wenjia Yang, Lingli Zhou, Xueyao Han, Simin Zhang, Linong Ji · 2017 · Journal of Diabetes Investigation
49. Real‐world weight‐loss effectiveness of glucagon‐like peptide‐1 agonists among patients with type 2 diabetes: A retrospective cohort study
    White, Gretchen E., Shu, Ingrid, Rometo, David, Arnold, Jon, Korytkowski, Mary, Luo, Jing · 2023 · Obesity
50. A network meta‐analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo
    David Alexander Scott, Kristina Secnik Boye, Louise Timlin, James F. Clark, Jennie H. Best · 2012 · Diabetes Obesity and Metabolism
51. Antidiabetic Drugs and Statins in Nonalcoholic Fatty Liver Disease
    Sneha Kothari, Hiteshi Dhami-Shah, Samir R. Shah · 2019 · Journal of Clinical and Experimental Hepatology
52. Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential
    Signe S. Torekov, Sten Madsbad, Jens Juul Holst · 2011 · Obesity Reviews
53. Peptide‐based multi‐agonists: a new paradigm in metabolic pharmacology
    Sara J. Brandt, Timo D. Müller, Richard D. DiMarchi, M. Tschöp, Kerstin Stemmer · 2018 · Journal of Internal Medicine
54. Effects of GLP-1 agonists on proportion of weight loss in obesity with or without diabetes: Systematic review and meta-analysis
    Vosoughi, Kia, Salman Roghani, Roham, Camilleri, Michael · 2022 · Obesity Medicine
55. Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity
    Chunjun Li, Jing Li, Qiu-Mei Zhang, Lin Lv, Rui Chen, Chun-feng Lv, Pei Yu, Demin M. Yu · 2012 · Cardiovascular Diabetology
56. The Glucagon-Like Peptide-1 Receptor Agonist, Liraglutide, Attenuates the Progression of Overt Diabetic Nephropathy in Type 2 Diabetic Patients
    Shigeki Imamura, Keiji Hirai, Aizan Hirai · 2013 · The Tohoku Journal of Experimental Medicine
57. Obesity treatment: novel peripheral targets
    Benjamin C. T. Field, Owais B. Chaudhri, Stephen Robert Bloom · 2009 · British Journal of Clinical Pharmacology
58. The future of incretin‐based therapy: novel avenues—novel targets
    Bo Åhrén · 2011 · Diabetes Obesity and Metabolism
59. Potential side effects to GLP-1 agonists: understanding their safety and tolerability
    Agostino Consoli, Gloria Formoso · 2014 · Expert Opinion on Drug Safety
60. Combining GLP ‐1 receptor agonists with insulin: therapeutic rationales and clinical findings
    Jens Juul Holst, Tina Vilsbøll · 2012 · Diabetes Obesity and Metabolism
61. Liraglutide: A Once-Daily Incretin Mimetic for the Treatment of Type 2 Diabetes Mellitus
    Joshua J. Neumiller, R. Keith Campbell · 2009 · Annals of Pharmacotherapy
62. Liraglutide
    Katherine F Croom, Paul L. McCormack · 2009 · Drugs
63. Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus
    Suzuki, Daisuke, Toyoda, Masao, Kimura, Moritugu, Miyauchi, Masaaki, Yamamoto, Naoyuki, Sato, Hiroki, Tanaka, Eitaro, Kuriyama, Yusuke, Miyatake, Han, Abe, Makiko et al. · 2013 · Internal Medicine
64. The new era of drug therapy for obesity: the evidence and the expectations
    Jones, Ben J., Bloom, Stephen R. · 2015 · Drugs
65. Comparison of the Efficacy and Tolerability Profile of Liraglutide, a Once-Daily Human GLP-1 Analog, in Patients With Type 2 Diabetes ≥65 and <65 Years of Age: A Pooled Analysis from Phase III Studies
    Bruce W. Bode, Jason Brett, Ali Falahati, Richard E. Pratley · 2011 · The American Journal of Geriatric Pharmacotherapy
66. Exenatide therapy in insulin-treated type 2 diabetes and obesity
    U. A. Nayak, Jyothish P. Govindan, V. Baskar, D. Kalupahana, Baldev Malkit Singh · 2010 · QJM
67. Long-Term Effectiveness of Liraglutide for Weight Management and Glycemic Control in Type 2 Diabetes
    Mirabelli, Maria, Chiefari, Eusebio, Caroleo, Patrizia, Arcidiacono, Biagio, Corigliano, Domenica Maria, Giuliano, Stefania, Brunetti, Francesco Saverio, Tanyolaç, Sinan, Foti, Daniela Patrizia, Puccio, Luigi et al. · 2019 · International Journal of Environmental Research and Public Health
68. The Effect of Liraglutide Added to U-500 Insulin in Patients with Type 2 Diabetes and High Insulin Requirements
    Wendy S. Lane, Stephen L. Weinrib, Jonathan M. Rappaport · 2011 · Diabetes Technology & Therapeutics
69. Regulation of lipid metabolism by energy availability: a role for the central nervous system
    Rubén Nogueiras, Miguel López, Carlos Diéguez · 2009 · Obesity Reviews
70. Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management
    William T. Cefalu, John B. Buse, Stefano Del Prato, Philip Home, Derek LeRoith, Michael Albrecht Nauck, Itamar Raz, Julio Rosenstock, Matthew C. Riddle · 2014 · Diabetes Care
71. Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes
    Erin St. Onge, Shannon A. Miller · 2010 · Expert Opinion on Biological Therapy
72. Predictors and Consequences of Severe Hypoglycemia in Adults with Diabetes - A Systematic Review of the Evidence
    Hanna E. Bloomfield, Nancy L. Greer, David R. Newman, Roderick H. MacDonald, Maureen H. Carlyle, PATRICK J. FITZGERALD, Indulis R. Rutks, Timothy J Wilt · 2012
73. Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin
    Melanie Jane Davies, Richard E. Pratley, Mette Hammer, Anne Bloch Thomsen, Robert M Cuddihy · 2010 · Diabetic Medicine
74. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: A systematic review and meta-analysis
    Pinelli, Nicole R, Hurren, Kathryn M · 2011 · Annals of Pharmacotherapy
75. Liraglutide induces beige fat development and promotes mitochondrial function in diet induced obesity mice partially through AMPK-SIRT-1-PGC1-α cell signaling pathway
    Zhou, Joseph, Poudel, Anil, Chandramani-Shivalingappa, Prashanth, Xu, Biao, Welchko, Ryan, Li, Lixin · 2019 · Endocrine
76. Type 2 diabetes and obesity in adults
    Whitmore, Catherine · 2010 · British Journal of Nursing
77. Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36‐week, randomized, double‐blind, parallel‐group trial
    Yutaka Seino, Shizuka Kaneko, Shuichi Fukuda, Takeshi Osonoi, Toshihiko Shiraiwa, Keiji Nishijima, Heidrun Bosch‐Traberg, Kohei Kaku · 2015 · Journal of Diabetes Investigation
78. Practical Use of Pharmacotherapy for Obesity
    Leon I. Igel, Rekha B. Kumar, Katherine H. Saunders, Louis J. Aronne · 2017 · Gastroenterology
79. Incretin‐based therapies
    Anthony H. Stonehouse, Tamara Darsow, David G. Maggs · 2011 · Journal of Diabetes
80. Willingness to pay for health improvements associated with anti-diabetes treatments for people with type 2 diabetes
    JOHAN H. JENDLE, Ole Torffvit, Martin Ridderstråle, Morten Lammert, Åsa Ericsson, Mette Bøgelund · 2010 · Current Medical Research and Opinion
81. Clinical Application of Incretin-Based Therapy: Therapeutic Potential, Patient Selection and Clinical Use
    David M. Kendall, Robert M Cuddihy, Richard M. Bergenstal · 2009 · European Journal of Internal Medicine
82. The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity
    James D. Crane, Barbara M. McGowan · 2015 · Therapeutic Advances in Chronic Disease
83. Physiology and Pharmacology of Effects of GLP-1-based Therapies on Gastric, Biliary and Intestinal Motility
    Jalleh, Ryan J, Marathe, Chinmay S, Rayner, Christopher K, Jones, Karen L, Umapathysivam, Mahesh M, Wu, Tongzhi, Quast, Daniel R, Plummer, Mark P, Nauck, Michael A, Horowitz, Michael · 2024 · Endocrinology
84. Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add‐on to metformin monotherapy in Type 2 diabetes mellitus
    Melanie Jane Davies, Barrie Chubb, Inger Smith, William J. Valentine · 2011 · Diabetic Medicine
85. Beyond glucose lowering: Glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system
    Vergès, B., Bonnard, C., Renard, E. · 2011 · Diabetes &amp; Metabolism
86. Impact of GLP-1 Receptor Agonists on Major Gastrointestinal Disorders for Type 2 Diabetes Mellitus: A Mixed Treatment Comparison Meta-Analysis
    Sun, Feng, Yu, Kai, Yang, Zhirong, Wu, Shanshan, Zhang, Yuan, Shi, Luwen, Ji, Linong, Zhan, Siyan · 2012 · Experimental Diabetes Research
87. Acute Pancreatitis Associated with Liraglutide
    Phillip H. Lee, M. David Stockton, Andrea S. Franks · 2011 · Annals of Pharmacotherapy
88. Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time
    Baptist Gallwitz, Allan Arthur Vaag, Ali Falahati, Sten Madsbad · 2009 · International Journal of Clinical Practice
89. GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations
    Maria Jersild Jespersen, Filip Krag Knop, Mikkel Christensen · 2012 · Expert Opinion on Drug Metabolism & Toxicology
90. Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus
    Kira B. Harris, Delilah J. McCarty · 2014 · Therapeutic Advances in Endocrinology and Metabolism
91. Pharmacotherapy for Obesity
    Katherine H. Saunders, Alpana P. Shukla, Leon I. Igel, Rekha B. Kumar, Louis J. Aronne · 2016 · Endocrinology and Metabolism Clinics of North America
92. Therapeutic advances in obesity management: an overview of the therapeutic interventions
    Moody Al Roomy, Kainat Hussain, Hawraa M. Behbehani, Jenna Abu-Farha, Rayan Al-Harris, Aishwarya Mariam Ambi, Mohammed Altigani Abdalla, Fahd Al‐Mulla, Mohamed Abu‐Farha, Jehad Ahmed Abubaker · 2024 · Frontiers in Endocrinology
93. Multinational Internet-based survey of patient preference for newer oral or injectable Type 2 diabetes medication
    Marco DiBonaventura, Samuel C. Wagner, Cynthia J. Girman, Kimberly Goodnow Brodovicz, Qiaoyi Zhang, Ying Qiu, P Sriram, Larry Radican · 2010 · Patient Preference and Adherence
94. Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors
    L. Kurukulasuriya, J. Sowers · 2010 · Cardiovascular Diabetology
95. Inventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity
    Lotte Bjerre Knudsen · 2019 · ACS Pharmacology & Translational Science
96. Cardiometabolic effects of a new class of antidiabetic agents
    Desouza, Cyrus V., Gupta, Namita, Patel, Anery · 2015 · Clinical Therapeutics
97. Liraglutide in clinical practice: dosing, safety and efficacy: Liraglutide in practice
    Peterson, G. E., Pollom, R. D. · 2010 · International Journal of Clinical Practice
98. Liraglutide Increases the Catabolism of Apolipoprotein B100–Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertase Subtilisin/Kexin Type 9 Expression
    Vergès, Bruno, Duvillard, Laurence, Pais de Barros, Jean Paul, Bouillet, Benjamin, Baillot-Rudoni, Sabine, Rouland, Alexia, Petit, Jean Michel, Degrace, Pascal, Demizieux, Laurent · 2021 · Diabetes Care
99. Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study
    Preman Kumarathurai, Christian Anholm, Olav Wendelboe Nielsen, Ole Peter Kristiansen, Jens Mølvig, Sten Madsbad, Steen B. Haugaard, Ahmad Sajadieh · 2016 · Cardiovascular Diabetology
100. GLP-1 Agonists and Dipeptidyl-Peptidase IV Inhibitors
     Baptist Gallwitz · 2011 · Handbook of experimental pharmacology